Company news

Arcutis Biotherapeutics, Inc. news in 2023

Arcutis Biotherapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

December 14, 2023

FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

November 28, 2023

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

November 2, 2023

Arcutis to Report Third Quarter 2023 Financial Results

October 24, 2023

New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials

October 19, 2023

Arcutis Announces Pricing of $100 Million Public Offering

October 18, 2023

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

October 12, 2023

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

October 5, 2023

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

September 26, 2023

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

September 24, 2023

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

September 18, 2023

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

September 11, 2023

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

September 6, 2023

Arcutis to Present at Upcoming Investor Conference

September 4, 2023

Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report

August 30, 2023

Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%

August 28, 2023

Arcutis Appoints Interim Chief Financial Officer (CFO)

August 17, 2023

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

August 9, 2023

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

August 7, 2023

Arcutis to Report Second Quarter Financial Results

July 23, 2023

Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark

July 16, 2023

Arcutis Announces Leadership Transition

May 23, 2023

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023

Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

May 1, 2023

Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older

April 27, 2023

Arcutis to Report First Quarter Financial Results

April 24, 2023

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

April 17, 2023

Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million

April 4, 2023

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

March 17, 2023

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

March 8, 2023

Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 27, 2023

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

February 20, 2023

Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference

February 7, 2023

Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

January 13, 2023

Calls in 2023

Decks in 2023